Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
Clinical trial NCT05651178 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05651178
- Sponsor
- Hrain Biotechnology Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-12
- Primary completion
- 2024-11-30
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.